(Q34802885)

4 August 2017

1 reference

title

5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy (English)

1 reference

4 August 2017

Shufeng Zhou

1

1 reference

4 August 2017

Philip Kestell

series ordinal

2

1 reference

4 August 2017

Bruce C Baguley

series ordinal

3

1 reference

4 August 2017

James W Paxton

series ordinal

4

1 reference

4 August 2017

publication date

1 August 2002

1 reference

Investigational New Drugs

4 August 2017

published in

1 reference

4 August 2017

volume

20

1 reference

4 August 2017

issue

3

1 reference

4 August 2017

page(s)

281-295

1 reference

Predictability of the covalent binding of acidic drugs in man.

4 August 2017

cites work

1 reference

12 December 2020

Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man.

1 reference

12 December 2020

Structure and function of uridine diphosphate glucuronosyltransferases

1 reference

12 December 2020

Suppression of serum tumour necrosis factor-alpha by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5,6-dimethylxanthenone-4-acetic acid

1 reference

12 December 2020

Reversible binding of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid to plasma proteins and its distribution into blood cells in various species

1 reference

12 December 2020

Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.

1 reference

12 December 2020

Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes

1 reference

12 December 2020

Interferon-inducible protein 10 induction and inhibition of angiogenesis in vivo by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).

1 reference

12 December 2020

3D-QSAR methods on the basis of ligand-receptor complexes. Application of COMBINE and GRID/GOLPE methodologies to a series of CYP1A2 ligands

1 reference

12 December 2020

Evidence for the production of nitric oxide by activated macrophages treated with the antitumor agents flavone-8-acetic acid and xanthenone-4-acetic acid

1 reference

12 December 2020

Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol.

1 reference

12 December 2020

In vitro and in vivo kinetic interactions of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid with thalidomide and diclofenac

1 reference

12 December 2020

Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity

1 reference

12 December 2020

Correlation between immune and vascular activities of xanthenone acetic acid antitumor agents

1 reference

12 December 2020

Blood flow failure as a major determinant in the antitumor action of flavone acetic acid.

1 reference

12 December 2020

Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid

1 reference

12 December 2020

Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes

1 reference

12 December 2020

Antitumor effects of alpha-interferon and gamma-interferon on a murine renal cancer (Renca) in vitro and in vivo

1 reference

12 December 2020

Activation of LPS-inducible genes by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid in primary murine macrophages. Dissection of signaling pathways leading to gene induction and tyrosine phosphorylation.

1 reference

12 December 2020

Inhibition of human cytochrome P450 1A2 by flavones: a molecular modeling study.

1 reference

12 December 2020

Flavone acetic acid--preclinical and clinical activity

1 reference

12 December 2020

Induction of multiple cytokine gene expression and IRF-1 mRNA by flavone acetic acid in a murine macrophage cell line

1 reference

12 December 2020

Induction of tumor necrosis factor-alpha messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6-dimethylxanthenone-4-acetic acid (NSC 640488).

1 reference

12 December 2020

Effects of the serotonin receptor antagonist cyproheptadine on the activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA).

1 reference

12 December 2020

Plasma pharmacokinetics of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in a phase I trial

1 reference

12 December 2020

Quantitative structure-activity relationships in substrates, inducers, and inhibitors of cytochrome P4501 (CYP1).

1 reference

12 December 2020

Characterization of the major metabolites of flavone acetic acid and comparison of their disposition in humans and mice

1 reference

12 December 2020

The effect of 5,6-dimethylxanthenone-4-acetic acid on tumour necrosis factor production by human immune cells.

1 reference

12 December 2020

Augmentation of natural killer activity, induction of IFN and development tumor immunity during the successful treatment of established murine renal cancer using flavone acetic acid and IL-2.

1 reference

12 December 2020

Biological basis for extrapolation across mammalian species.

1 reference

12 December 2020

Role of pharmacokinetics and metabolism in drug discovery and development

1 reference

12 December 2020

Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids

1 reference

12 December 2020

Plasma pharmacokinetics of the antitumour agents 5,6-dimethylxanthenone-4-acetic acid, xanthenone-4-acetic acid and flavone-8-acetic acid in mice

1 reference

12 December 2020

Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid

1 reference

12 December 2020

Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastine, and colchicine: relation to vascular effects

1 reference

12 December 2020

Properties of acyl glucuronides: implications for studies of the pharmacokinetics and metabolism of acidic drugs

1 reference

12 December 2020

Cytokine induction and therapeutic synergy with interleukin-2 against murine renal and colon cancers by xanthenone-4-acetic acid derivatives

1 reference

12 December 2020

Mechanisms of enhancement of the antitumour activity of melphalan by the tumour-blood-flow inhibitor 5,6-dimethylxanthenone-4-acetic acid

1 reference

12 December 2020

Use of in vitro human metabolism studies in drug development. An industrial perspective

1 reference

12 December 2020

Species differences in the metabolism of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in vitro: implications for prediction of metabolic interactions in vivo

1 reference

12 December 2020

Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid

1 reference

12 December 2020

Antitumour activity of the novel immune modulator 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice lacking the interferon-gamma receptor.

1 reference

12 December 2020

Identification and reactivity of the major metabolite (beta-1-glucuronide) of the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in humans

1 reference

12 December 2020

Role of T cells and tumour necrosis factor in antitumour activity and toxicity of flavone acetic acid

1 reference

12 December 2020

Determination of the covalent adducts of the novel anti-cancer agent 5,6-dimethylxanthenone-4-acetic acid in biological samples by high-performance liquid chromatography

1 reference

12 December 2020

Plasma disposition, metabolism and excretion of the experimental antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the mouse, rat and rabbit

1 reference

12 December 2020

Reduction of tumor blood flow by flavone acetic acid: a possible component of therapy.

1 reference

12 December 2020

Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-acetic acid

1 reference

12 December 2020

Metabolism and elimination of 5,6-dimethylxanthenone-4-acetic acid in the isolated perfused rat liver.

1 reference

12 December 2020

Anti-tumour activity of flavone acetic acid (NSC 347512) in mice--influence of immune status

1 reference

12 December 2020

Modulation of the pharmacokinetics of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice by thalidomide

1 reference

12 December 2020

Inhibition of human liver cytochrome P-450 1A2 by the class IB antiarrhythmics mexiletine, lidocaine, and tocainide.

1 reference

12 December 2020

Serotonin involvement in the antitumour and host effects of flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid

1 reference

12 December 2020

Comparison of the effects of flavone acetic acid, fostriecin, homoharringtonine and tumour necrosis factor alpha on colon 38 tumours in mice

1 reference

12 December 2020

Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors

1 reference

12 December 2020

Preclinical prediction of factors influencing the elimination of 5,6-dimethylxanthenone-4-acetic acid, a new anticancer drug

1 reference

12 December 2020

Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: Extrapolation of data to benzodiazepines and phenytoin

1 reference

12 December 2020

Advances in drug metabolism screening

1 reference

12 December 2020

Determination of two major metabolites of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid in hepatic microsomal incubations by high-performance liquid chromatography with fluorescence detection

1 reference

12 December 2020

Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo

1 reference

12 December 2020

Flavone acetic acid: a novel agent with preclinical antitumor activity against colon adenocarcinoma 38 in mice

1 reference

12 December 2020

Effect of flavone acetic acid (NSC 347,512) on splenic cytotoxic effector cells and their role in tumour necrosis.

1 reference

12 December 2020

Induction of STAT and NFkappaB activation by the antitumor agents 5,6-dimethylxanthenone-4-acetic acid and flavone acetic acid in a murine macrophage cell line

1 reference

12 December 2020

Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs

1 reference

12 December 2020

Identification of the human liver cytochrome P450 isoenzyme responsible for the 6-methylhydroxylation of the novel anticancer drug 5,6-dimethylxanthenone-4-acetic acid

1 reference

12 December 2020

Tumor-dependent increased plasma nitrate concentrations as an indication of the antitumor effect of flavone-8-acetic acid and analogues in mice

1 reference

12 December 2020

Synthesis of the CC-chemokines MIP-1alpha, MIP-1beta, and RANTES is associated with a type 1 immune response.

1 reference

12 December 2020

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

1 reference

12 December 2020

Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy

1 reference

12 December 2020

Serotonin antagonists

1 reference

12 December 2020

The structure and function of the UDP-glucuronosyltransferase gene family

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1016215015530

1 reference

Dimensions Publication ID

4 August 2017

1045426122

0 references

1 reference